The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of galunisertib (LY2157299) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC).
 
Kim Anna Reiss
Research Funding - Clovis Oncology; Lilly
 
Edgar Ben-Josef
No Relationships to Disclose
 
Nevena Damjanov
Honoraria - Daiichi Sankyo (I); Sirtex Medical
Consulting or Advisory Role - Amgen; Bayer; Celgene
 
Maarouf Hoteit
No Relationships to Disclose
 
Mark H. O'Hara
No Relationships to Disclose
 
Thomas Benjamin Karasic
No Relationships to Disclose
 
Ursina R. Teitelbaum
No Relationships to Disclose
 
Charles Schneider
No Relationships to Disclose
 
Peter J. O'Dwyer
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Forty Seven; Genentech
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics
 
Erica L. Carpenter
Research Funding - Janssen; Merck
Travel, Accommodations, Expenses - Silicon Biosytems
 
Rosemarie Mick
Stock and Other Ownership Interests - Editas Medicine
Consulting or Advisory Role - Infiniti Medical
 
Robert H. Vonderheide
Honoraria - Celgene; Genentech
Consulting or Advisory Role - Celldex; Lilly
Research Funding - Lilly (Inst)